Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,119 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05147844RecruitingPhase 2
Toripalimab plus radiation for limited-spread nose cancer
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06819293RecruitingPhase 1
IB-T101 injection for advanced kidney cancer
This trial tests an experimental injection called IB-T101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. It aims to see if the treatment is safe and possibly effective.
Wuhan, HubeiAges 18 years+ - NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT05173246RecruitingPhase 2
First-line treatment study for advanced small cell esophageal cancer
This Phase 2 trial tests JS001 plus TP as a first treatment for people with advanced or unresectable small cell esophageal cancer. It aims to see how well this combination controls the cancer and improves outcomes compared with starting treatment with standard options.
Guangzhou, GuangdongAges 18–75 - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT05774483Recruiting
Check nodes in early mouth cancer using a biopsy or planned neck surgery
This trial studies two ways to check whether early oral cavity cancer has spread to nearby neck lymph nodes. It compares sentinel node biopsy versus limited elective neck dissection to see which approach is more useful for people with node-negative tongue or inner-cheek cancers.
Mumbai, MaharashtraAges 18–80 - NCT06738251RecruitingPhase 3
Study of SHR-A2102 for advanced bladder cancer
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT06794229RecruitingPhase 2
Zanzalintinib plus nivolumab before surgery for advanced kidney cancer
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06794372RecruitingPhase 2
68Ga-FAPI-46 PET scan for head and neck cancer staging
This trial tests a new type of PET scan that uses a special tracer (68Ga-FAPI-46) to see if it can better show the extent of head and neck cancers before surgery. It may help doctors plan your treatment more accurately.
Lausanne, Canton of VaudAges 18 years+ - NCT06796114Recruiting
Biomarkers in advanced liver cancer treated with tremelimumab/durvalumab
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
BesançonAges 18 years+ - NCT06642220RecruitingPhase 2
Y-90 radioembolization for kidney cancer
This trial tests a procedure called Y-90 radioembolization for patients with kidney cancer tumors larger than 4 cm who cannot have or choose not to have surgery. The treatment delivers tiny radioactive beads through a blood vessel to the tumor to destroy cancer cells while limiting damage to healthy tissue.
London, OntarioAges 18 years+ - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT06789198RecruitingPhase 1
Peptide vaccine for fibrolamellar liver cancer
This trial tests a patient-specific vaccine for people who have a rare type of liver cancer called fibrolamellar hepatocellular carcinoma (FL-HCC), or another cancer with the same genetic change. The vaccine is given after the cancer has been completely removed or treated, and it aims to teach your immune system to recognize and destroy any cancer cells that might be left.
TübingenAges 12 years+ - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT04268121RecruitingPhase 2
Neoadjuvant chemotherapy before surgery for certain digestive neuroendocrine cancers
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
AmiensAges 18 years+ - NCT06774131RecruitingPhase 3
Study of UGN-104 for low-grade upper tract urothelial cancer
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
Homewood, AlabamaAges 18 years+ - NCT06781567RecruitingPhase 2
HG146 for advanced adenoid cystic carcinoma
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06780475Recruiting
Lab test for a new Merkel cell cancer treatment
This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.
Boulogne-BillancourtAges 18 years+ - NCT06778317Recruiting
Blood test to predict liver cancer in cirrhosis patients
This trial tests if a simple blood test can help predict who with cirrhosis might develop liver cancer, so doctors can monitor and treat those patients earlier.
Vandœuvre-lès-NancyAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Tucson, ArizonaAges 18 years+ - NCT06763640Enrolling by invitation
TILs as a predictor in nasopharyngeal cancer
This study looks at how immune cells called TILs (tumor-infiltrating lymphocytes) in your tumor tissue might predict outcomes for nasopharyngeal cancer. It may help doctors better understand your cancer and guide future treatment decisions.
Nanchang, JiangxiAges 18–70
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,119 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.